<bill session="107" type="h" number="3047" updated="2013-07-14T18:58:06-04:00">
  <state datetime="2001-10-04">REFERRED</state>
  <status>
    <introduced datetime="2001-10-04"/>
  </status>
  <introduced datetime="2001-10-04"/>
  <titles>
    <title as="introduced" type="short">Best Pharmaceuticals for Children Act</title>
    <title as="introduced" type="official">To amend the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act with respect to pediatric studies of drugs, and for other purposes.</title>
  </titles>
  <sponsor id="400425"/>
  <cosponsors>
    <cosponsor id="400553" joined="2001-10-04"/>
    <cosponsor id="400050" joined="2001-10-04"/>
    <cosponsor id="400106" joined="2001-10-04"/>
    <cosponsor id="400110" joined="2001-10-04"/>
    <cosponsor id="400160" joined="2001-10-04"/>
    <cosponsor id="400308" joined="2001-10-04"/>
    <cosponsor id="400391" joined="2001-10-04"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2001-10-04">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2001-10-15">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Committee on Energy and Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative fees"/>
    <term name="Administrative procedure"/>
    <term name="Administrative remedies"/>
    <term name="Bioethics"/>
    <term name="Child health"/>
    <term name="Clinical trials"/>
    <term name="Commerce"/>
    <term name="Competitive bidding"/>
    <term name="Cost plus contracts"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug approvals"/>
    <term name="Drug industry"/>
    <term name="Economics and public finance"/>
    <term name="Executive reorganization"/>
    <term name="Families"/>
    <term name="Foundations"/>
    <term name="Government operations and politics"/>
    <term name="Government paperwork"/>
    <term name="Governmental investigations"/>
    <term name="Human experimentation in medicine"/>
    <term name="Informed consent (Medical law)"/>
    <term name="Intellectual property"/>
    <term name="Labeling"/>
    <term name="Law"/>
    <term name="Medical ethics"/>
    <term name="Medical research"/>
    <term name="Parent and child"/>
    <term name="Patents"/>
    <term name="Pharmaceutical research"/>
    <term name="Science, technology, communications"/>
    <term name="Social welfare"/>
    <term name="User charges"/>
  </subjects>
  <amendments/>
  <summary>10/4/2001--Introduced.
Best Pharmaceuticals for Children Act - Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services to establish a pediatric drug studies program. Directs the Secretary to establish and maintain a list of drugs for which: (1) there is an approved market application and no patent or market exclusivity protection; and (2) additional pediatric safety and effectiveness studies are needed. Authorizes the Secretary to require holders or sponsors of certain drugs to conduct such studies on a contract payment basis. Requires the Secretary to give preference to the holders or sponsors of drugs for which the studies are requested rather than required when awarding test contracts.Sets forth procedures for making labeling changes for already marketed drugs, if so indicated by such studies.Eliminates the user fee waiver for pediatric supplements to a human drug application.Sets forth requirements for the additional six-month exclusivity period for new or already-marketed pediatric drugs.Amends Title IV of the Public Health Service Act to direct the Secretary to establish the Foundation for Pediatric Research to support research on drugs lacking exclusivity for which pediatric studies are needed.Directs the Secretary to establish an Office of Pediatric Therapeutics within the Office of the Commissioner of Food and Drugs, which shall coordinate all FDA pediatric activities.Directs the Secretary to contract with the Institute of Medicine to review Federal regulations, reports, and support for research involving children, with particular attention to issues of compensation, informed consent, and risk/benefits assessments in terms of research versus therapeutic treatment.</summary>
</bill>
